Provider review
Alinwell Review: Nineteen Peptides, Published Lab Results, and Descriptions Attached to the Wrong Products
Alinwell does the rare thing and the careless thing on the same page. It publishes seventeen certificates of analysis, naming the laboratory and the compounder, so a buyer can read a potency result instead of being told one exists. Then it describes eight of its nineteen programs with a sentence belonging to one ingredient — a four-peptide blend at $379 is introduced as "a copper peptide", and ipamorelin is never described at all. The evidence underneath is thinner than any of the descriptions suggest.
The only peptide seller in this batch that shows you a lab result — and it describes eight of its nineteen products with a sentence belonging to something else in the vial.
Worth trusting if
- You want to read an actual certificate of analysis rather than be told testing happens
- You want the pharmacy and the testing laboratory identifiable, even if you have to open a PDF to find them
- You are buying tesamorelin or PT-141, the two molecules here with completed phase 3 trials behind them
Be skeptical if
- You are buying a blend, because its description belongs to one ingredient
- You want the claim on the card to be what was tested — on nine of eleven molecules it is not
- You want the compounding class stated, which this site never does
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens alinwell.com. A link is not a recommendation to take anything.
Provenance
What Alinwell actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin — Priced twice on Alinwell's own site: $249/mo on the peptides page and $349/mo on the homepage, for the same product on the same day.
- NAD+ Injection — Priced twice on Alinwell's own site: $199/mo on the peptides page against $249/mo on the homepage.
- MOTS-C — $279/mo, quoted as a floor rather than a rate.
- Tesamorelin — $299/mo as a floor. The blend beside it is dearer and carries this same sentence.
- BPC-157 — $250/mo for BPC-157 alone. Alinwell sells five further products containing it, from $199 to $379, all carrying this same sentence.
- GHK-Cu — $249/mo. The same sentence is printed on two blends that are mostly other peptides.
- Epithalon — $249/mo alone, or $249 paired with GHK-Cu, where the pair carries this sentence.
- Thymosin A-1 — $299/mo, the only product in Alinwell's immune category.
- DSIP — $249/mo. A three-peptide blend at $299 carries this same sentence.
- Semax / Selank — $299/mo, sold as a pair rather than separately.
- PT-141 — $249/mo, the only product in Alinwell's sexual-health category.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
6
Molecules with human evidence
For the use they are sold for, out of 11 products reviewed here. The evidence belongs to the molecule, not to Alinwell.
8
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Alinwell’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
SermorelinSermorelin · Compounded (503A)Claim reaches past the trials
“A growth-hormone-releasing hormone used to support natural GH production, recovery, and sleep.”
Read on the Alinwell site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery or sleep quality as an outcome in healthy adults. A parallel ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
The first third of the sentence is the best-supported claim on this page and the rest is not. Sermorelin does raise growth hormone — that is what all 19 randomized trials measured, and it is why the molecule exists. "Recovery" and "sleep" are a different matter: no trial in that literature uses either as an outcome, in healthy adults or anyone else. A reader is being shown one real finding and two that were never tested, in a single sentence, with nothing marking which is which.1
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“A cellular coenzyme used to support energy, mental clarity, and healthy aging.”
Read on the Alinwell site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Three claims, none of them tested for this product. Energy, mental clarity and healthy aging are exactly the outcomes an injected NAD+ trial would have to measure, and no such trial has reported. The literature people point to when asked is about oral precursors, which are different molecules taken a different way — the results do not carry across any more than oral iron carries across to an infusion.2
MOTS-CMOTS-c · Compounded (503A)No trial supports this claim
“A mitochondrial-derived peptide used to support cellular energy, metabolism, and exercise capacity.”
Read on the Alinwell site, September 2026
Phase 2 only
- NCT07505745 MOTS-MET — Phase 2, recruiting, n=120. Recruiting, not reporting. No completed human efficacy result exists for a metabolic outcome.
A trial exists and it has not finished. MOTS-MET is recruiting 120 participants for a metabolic outcome, which is the right question — but a recruiting trial has produced no result, so there is nothing yet for a claim about energy, metabolism or exercise capacity to rest on. This is the most common shape on this site: not an absent literature, an unfinished one.3
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“A growth-hormone-releasing analog used to support fat metabolism and healthy body composition.”
Read on the Alinwell site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. The pivotal trial of tesamorelin in HIV patients with excess abdominal fat. The outcome measured was visceral abdominal fat, in that population.
- NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.
Tesamorelin has the strongest trial record of any peptide on this menu, and it was earned in a population Alinwell is not selling to. Both phase 3 trials studied HIV-associated lipodystrophy — a specific, disfiguring accumulation of visceral fat — and the outcome was visceral abdominal fat in those patients. "Fat metabolism and healthy body composition" in a general adult is an extrapolation from that, and the page gives a reader no way to see the gap.4,5
BPC-157BPC-157 · Compounded (503A)No trial supports this claim
“Body Protection Compound — used to support tissue repair, gut health, and recovery.”
Read on the Alinwell site, September 2026
Phase 1 only
What the trials show for BPC-157
- NCT02637284 — Phase 1, unknown status, n=42. The registry record for BPC-157 in humans sits at phase 1 — the stage that establishes tolerability, not effect — and its status is unknown rather than completed.
Phase 1 asks whether a dose is tolerated. It does not measure whether tissue repairs faster, whether a gut symptom improves, or whether anyone recovers sooner, and those are the three things this sentence promises. The registry record's status is not even "completed" — it is unknown, which means the registry itself has lost track of whether it finished.6
GHK-CuGHK-Cu · Compounded (503A)Claim reaches past the trials
“A copper peptide used to support skin, collagen, hair, and tissue regeneration.”
Read on the Alinwell site, September 2026
Phase 2 only
What the trials show for GHK-Cu
- NCT07437586 — Phase 2, recruiting, n=60. Acute skin wound healing, recruiting. The completed GHK-Cu record on the registry is a 27-participant study of facial skin quality; neither studies hair.
Three of the four nouns have something behind them and one has nothing. Skin, collagen and tissue are what the GHK-Cu literature is about — a small completed study of facial skin quality and a recruiting wound-healing trial. Hair is not studied in any of the registry's GHK-Cu records, in any form, and it is the word most likely to sell the product.7
EpithalonEpithalon (epitalon) · Compounded (503A)No trial supports this claim
“A peptide studied for supporting cellular longevity, sleep quality, and healthy aging.”
Read on the Alinwell site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search returned zero studies for "Epithalon", zero for the spelling "Epitalon" and zero for "Epithalamin" — no registered trial of this molecule exists anywhere in the registry, for any indication, under any spelling. In PubMed, a search restricted to the randomized-controlled-trial publication type returns zero records. The randomized literature a looser search surfaces tests EPITHALAMIN, a peptide extract of bovine pineal gland rather than the synthetic tetrapeptide, and comes from a single research group.
The word doing the work is "studied". Epithalon has no registered trial anywhere in the world under any of its three spellings, and no randomized-controlled-trial record in PubMed. What exists is a body of work on epithalamin, a bovine pineal extract, from one group — a different substance, not a version of this one. "Studied for" is technically survivable and reads as though a literature supports the outcomes named after it.8
Thymosin A-1Thymosin alpha-1 · Compounded (503A)Claim reaches past the trials
“An immune-modulating peptide used to support immune resilience and balance.”
Read on the Alinwell site, September 2026
Phase 3 trials
- NCT02867267 TESTS — Phase 3, completed, n=1,106. Thymosin alpha-1 in SEPSIS — a completed phase 3 trial of 1,106 critically ill patients. The largest and best-designed evidence for this molecule, in a population nobody buys peptides online to join.
This molecule has real phase 3 evidence, and every bit of it is in serious illness. Searched live on 2026-09-01, PubMed holds 64 randomized-trial records for thymosin alpha-1 and the registry holds 64 studies; reading them, they are hepatitis B, sepsis, severe pancreatitis, cirrhosis and cancer immunotherapy. Modulating immunity in a patient in intensive care is not the same claim as supporting "resilience and balance" in a well adult, and the second has not been tested.9
DSIPDSIP (delta sleep-inducing peptide) · Compounded (503A)Claim reaches past the trials
“Delta sleep-inducing peptide used to support deep, restorative sleep.”
Read on the Alinwell site, September 2026
No trial for this use
Searched live on 2026-09-01. The same searches were run for tirzepatide in the same pass to confirm they were working, and returned 2,451 PubMed records, 134 randomized-trial records and 278 registry studies. DSIP returns 544 PubMed records, 7 carrying the randomized-controlled-trial publication type, and ZERO registry studies — the single registry hit is an L-carnitine study that does not involve DSIP. Reading the 7 rather than counting them: two are false positives, including a cervical-spine screw-fixation trial where DSIP is an unrelated abbreviation. The genuine sleep trials are two, published in 1981 and 1992, both in patients with chronic insomnia. Nothing tests sleep quality in adults without a sleep disorder, and the most recent randomized sleep record is 34 years old.
There is old human sleep evidence here, which is more than most of this menu can say, and it is not evidence for what is being sold. Two randomized trials tested DSIP in people with chronic insomnia, in 1981 and 1992. No registered trial of this molecule exists today, and nothing has tested "deep, restorative sleep" in adults who sleep normally — the reader this page is written for.10
Semax / SelankSemax and Selank · Compounded (503A)No trial supports this claim
“Nootropic peptides used to support focus, mood, and cognitive resilience.”
Read on the Alinwell site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search returns zero records naming Semax and zero naming Selank. The published literature is not empty and the distinction matters: PubMed holds 207 records mentioning Semax, of which one carries the randomized-controlled-trial publication type — a 2007 Russian-language paper on motor neuron disease, not attention or cognition. It holds 68 mentioning Selank, of which two are randomized trials, both in the same Russian journal and both in anxiety disorders.
Three randomized trials exist across both molecules and none of them is about focus or cognition in a healthy person. Semax's single randomized record is in motor neuron disease; Selank's two are in anxiety disorders. "Nootropic" is doing the work of a finding here, and no registered trial of either molecule exists anywhere.11
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“A peptide used to support libido and sexual arousal in men and women.”
Read on the Alinwell site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
Half of this sentence rests on two large phase 3 trials and the other half rests on nothing. The RECONNECT trials enrolled 1,437 premenopausal WOMEN with hypoactive sexual desire disorder, and they are why an approved product exists. Alinwell sells the molecule for "men and women", and the men's half was not what those trials tested. The page also never mentions that an approved version of this molecule exists at all.12
Dispensing chain
Who actually fills your prescription
- Greenwich Rx — named as the client on eleven peptide certificates of analysis issued by Miraxis Labs, 8310 Miramar Mall, San Diego CA 92121, (858) 623-2740
- ViOS — named on two further certificates, both image-only scans with no address legible
- Emerald Compounding Pharmacy — 5325 Primrose Lake Circle, Suite A, Tampa, FL 33647, named on the semaglutide and tirzepatide certificates
- Boudreaux's New Drug Store — 404 E. Prien Lake Rd., Lake Charles, LA 70601, 337-436-7216, named on the second pair of GLP-1 certificates
Read the full account
Four pharmacies are identifiable and not one of them is named in Alinwell's prose. The site says only "Compounded in a U.S. pharmacy"; the names appear inside the certificates of analysis it links from its own peptides page, which is where a reader has to go to find them. A census on 2026-09-01 over the visible text and DOM of ten pages, all sixteen production script bundles and the raw payloads found zero occurrences of "503A", "503B" or "503" anywhere on the domain, and no medical group, telehealth platform or either. Its terms also ask the buyer to "voluntarily and unconditionally waive your right to have the prescription filled at a pharmacy of your choice" — a waiver in favor of a party the prose never names.
Read on the Alinwell site, September 2026.
Quality
Third-party testing, and what is published
Yes
Describes a testing regime
A described program, not a document.
Yes
Certificate of analysis readable
Read the full testing account
Seventeen certificates of analysis are linked from Alinwell's own pages and all seventeen return a readable document. Eleven peptide certificates come from Miraxis Labs in San Diego and name Greenwich Rx as the client; two more are image-only ViOS scans; four cover the GLP-1s from Emerald and Boudreaux's. The site's claim is "Every batch is independently, third-party lab tested for identity, potency, and sterility — compounded at a licensed U.S. pharmacy", and the certificates carry lot numbers, test dates and a beyond-use date, so the claim is checkable rather than asserted. Two gaps remain. The certificates are undated against any particular purchase, so a buyer cannot confirm the lot they receive is one of these; and one ViOS certificate reports a "Quantity Yield: 250 Vials", which describes a batch rather than a preparation for a named patient.
Read on the Alinwell site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Alinwell's FAQ says service is available across all 50 states and its homepage marquee says telehealth nationwide. The intake's own shipping-state selector offers 51 options, adding the District of Columbia. No enumerated list appears in the company's prose anywhere, so the selector is the widest verified statement rather than the badge.
Read the full licensing claim
"Reviewed by a licensed provider" and "Compounded in a U.S. pharmacy" on every one of the nineteen peptide cards. No medical group, prescriber or state license number is published anywhere on the domain.
Read on the Alinwell site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It publishes seventeen certificates of analysis, linked from its own pages, all returning a readable document with lot numbers, test dates and a beyond-use date.
- The certificates name the testing laboratory — Miraxis Labs in San Diego, with a street address and a phone number — which is a check a reader can make independently.
- Four compounding pharmacies are identifiable from those certificates: Greenwich Rx, ViOS, Emerald Compounding Pharmacy and Boudreaux's New Drug Store.
Show 5 more
- Its testing claim is specific enough to be wrong: identity, potency and sterility, every batch, third-party. Most sellers here say "rigorously tested" and stop.
- The whole nineteen-program menu is priced on a public page before any questionnaire, which its GLP-1 line does not do.
- Its disclaimer states plainly that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA.
- Tesamorelin and PT-141 are real molecules with completed phase 3 trials, and Alinwell describes tesamorelin's mechanism accurately even where it overreaches on the population.
- No FDA warning letter for the company or any of the four pharmacies its certificates name.
- Eight of nineteen programs carry a description belonging to one ingredient. A four-peptide blend is introduced as "a copper peptide", and ipamorelin is never described anywhere on the site.
- The BPC-157 blends are filed under "Anti-Aging & Growth Hormone" while BPC-157 itself sits under "Recovery" — the same molecule in two categories on one page.
- Nine of the eleven molecules we graded claim more than their trials show, and two of them have no registered trial anywhere in the world.
Show 7 more
- The compounding class is never stated. A census across the whole domain found zero occurrences of 503A, 503B or 503.
- No prescriber or medical group is named anywhere, on a site that sells eleven prescription-only molecules.
- The pharmacies are named only inside certificate PDFs, so a reader who does not open one is told nothing about who compounds their medication.
- Its terms ask you to waive the right to fill your prescription at a pharmacy of your choice, in favor of a party the prose does not name.
- NAD+ and sermorelin are priced two different ways on the same site on the same day — $199 against $249, and $249 against $349.
- Every peptide price is a "from" floor while the GLP-1 prices are flat rates, so one site uses two pricing grammars.
- One certificate reports a 250-vial batch yield, which is not the language of a preparation compounded for a named patient.
Verdict
The bottom line
Open the certificates — Alinwell is one of the few sellers where that is possible, and it is the reason to consider it at all. Then read the card you are buying from twice. If the product name has a slash in it, the sentence underneath describes one of the ingredients and not the mixture, and on nine of the eleven single molecules the sentence reaches past what anyone has tested. The two exceptions are tesamorelin and PT-141, and both were trialled in populations you are probably not in.
Opens alinwell.com. A link is not a recommendation to take anything.
What it publishes that almost nobody does
Alinwell links seventeen certificates of analysis from its own peptides page. All seventeen open. Eleven of them are issued by Miraxis Labs, 8310 Miramar Mall, San Diego CA 92121, and name Greenwich Rx as the client. Two more are image-only scans from ViOS. Four cover the GLP-1s and name Emerald Compounding Pharmacy in Tampa and Boudreaux's New Drug Store in Lake Charles.
The site's testing claim is unusually specific:
"Every batch is independently, third-party lab tested for identity, potency, and sterility — compounded at a licensed U.S. pharmacy."
That is a sentence you can check, and checking it mostly works. The certificates carry lot numbers, test dates and beyond-use dates.
Two things it does not do. It never says whether the lot you receive is one of the lots shown. And one ViOS certificate reports a "Quantity Yield: 250 Vials" — the language of a batch, not of a preparation compounded against one patient's prescription.
Full analysis — 4 more sectionsThe descriptions belong to the wrong products · What the trials actually show · What is not published · The identical menu next door
The descriptions belong to the wrong products
Alinwell sells nineteen programs. Eight of them are blends, and every blend inherits a description from one ingredient.
| Program | The description printed under it | Whose sentence it is | |---|---|---| | BPC-157 / GHK-Cu / KPV / TB500 — $379 | "A copper peptide used to support skin, collagen, hair, and tissue regeneration" | GHK-Cu's | | BPC-157 / TB-500 / GHK-Cu — $349 | the same copper-peptide sentence | GHK-Cu's | | GHK-Cu / Epithalon — $319 | "A peptide studied for supporting cellular longevity, sleep quality…" | Epithalon's | | Tesamorelin / Ipamorelin — $299+ | "A growth-hormone-releasing analog used to support fat metabolism…" | Tesamorelin's | | BPC-157 / TB500 — $299 | "Body Protection Compound — used to support tissue repair…" | BPC-157's | | BPC-157 / KPV / TB500 — $329 | the same BPC-157 sentence | BPC-157's | | BPC-157 Acetate — $199 | the same BPC-157 sentence | BPC-157's | | DSIP / BPC / CJC — $329 | "Delta sleep-inducing peptide used to support deep, restorative sleep" | DSIP's |
A four-peptide product at $379 a month is introduced to the buyer as "a copper peptide". Ipamorelin is never described at all — not on its own card, because it does not have one, and not on the blend that contains it.
There is a filing error alongside it. BPC-157 sits under "Recovery, Healing & Tissue Repair"; the BPC-157 blends sit under "Anti-Aging & Growth Hormone". Same molecule, two categories, one page.
What the trials actually show
Of the eleven single molecules we graded, two have completed phase 3 trials, two have a trial that is still recruiting, one sits at phase 1, and four have no registered trial anywhere in the world.
Tesamorelin is the strongest record here — two completed phase 3 trials, 675 participants between them. 4 Both studied HIV-associated lipodystrophy, and the outcome was visceral abdominal fat in that population. Alinwell sells it for "fat metabolism and healthy body composition" generally.
PT-141 is next: RECONNECT 1 and 2, 1,437 premenopausal women with hypoactive sexual desire disorder, and the basis of an FDA approval. 12 Alinwell sells it "in men and women". The men's half was not tested, and the page never mentions the approved product exists.
Thymosin alpha-1 has 64 randomized-trial records and 64 registered studies, which sounds decisive until you read them. Searched live on 1 September 2026, they are hepatitis B, sepsis, severe pancreatitis, cirrhosis and cancer immunotherapy — including a completed phase 3 sepsis trial of 1,106 critically ill patients. 9 None of that is "immune resilience and balance" in a well adult.
Sermorelin is the sharpest case of a sentence that is one-third true. Nineteen randomized trials exist, the newest from 2005, and every one measures growth hormone secretion or growth in children. 1 The card promises "GH production, recovery, and sleep". The first is the best-supported claim on the whole page. The other two have never been an outcome in any of them.
Epithalon has no registered trial anywhere, under any of its three spellings, and no randomized-controlled-trial record in PubMed. 8 The literature people cite is about epithalamin, a bovine pineal extract — a different substance.
DSIP was searched live because this site had no position on it. The instrument was checked in the same pass: tirzepatide returned 2,451 PubMed records, 134 randomized-trial records and 278 registered studies, so the searches work. DSIP returned 544, 7 and zero. Reading the seven rather than counting them, two are false positives — one is a cervical-spine screw-fixation trial where DSIP is an unrelated abbreviation. The genuine sleep trials are two, from 1981 and 1992, both in patients with chronic insomnia. 10
KPV, which appears inside two blends, returned 57 PubMed records and two randomized trials — and both are false positives, an IVF gonadotropin trial and an erythropoietin trial in newborns. Neither involves KPV. It has no registered trial either, and it is never described on the site, because it only ever appears inside a blend named after something else.
What is not published
No prescriber. No medical group.. No compounding class — a census across ten pages, sixteen script bundles and the raw payloads found zero occurrences of "503A", "503B" or "503" anywhere on the domain.
That last absence sits oddly beside the certificates. Alinwell will show you a potency assay and will not tell you which section of the Food, Drug, and Cosmetic Act its pharmacy operates under.
The identical menu next door
Alinwell's nineteen peptide cards are byte-identical to Longevixx's — same names, same prices, same descriptions, same heading. We compared them as (name, price, description) triples on 1 September 2026: 19 of 19 matched.
The two companies are Alinwell LLC of Southlake, Texas and Longevixx LLC of Charlotte, North Carolina. Neither site mentions the other. Identical storefront copy points to a shared vendor or platform; it is not evidence of common ownership and we are not claiming any.
What it does mean is that the difference between them is visible. Longevixx publishes no certificates of analysis at all. Same menu, same prices, same sentences — and only one of the two will show you a lab result.
Questions
Frequently asked questions
Does Alinwell publish test results?
Yes, and that is the main reason to consider it. Seventeen certificates of analysis are linked from its own pages and all of them open, carrying lot numbers, test dates and beyond-use dates, issued by a named laboratory in San Diego. What it does not do is tell you whether the lot you receive is one of the lots shown.
Why does a four-peptide blend say it is a copper peptide?
Because the blend cards inherit a description from one ingredient. "BPC-157 / GHK-Cu / KPV / TB500" at $379 a month carries GHK-Cu's sentence, and seven other blends do the same thing with another ingredient's words. Ipamorelin is never described anywhere on the site, and KPV only ever appears inside a product named after something else.
Which of these peptides actually has evidence behind it?
Tesamorelin and PT-141 have completed phase 3 trials, though both were run in specific populations — HIV-associated lipodystrophy and premenopausal women with hypoactive sexual desire disorder. Thymosin alpha-1 has substantial phase 3 evidence in sepsis and hepatitis. Everything else on the menu is at phase 1, still recruiting, or has no registered trial at all.
Which pharmacy compounds Alinwell's peptides?
Greenwich Rx and ViOS, according to the certificates of analysis — but neither is named anywhere in Alinwell's own prose, which says only "compounded in a U.S. pharmacy". Its terms also ask you to waive the right to fill your prescription at a pharmacy of your choice, which is a waiver in favor of a company the site does not name.
Why is NAD+ priced two different ways?
Because Alinwell publishes two figures for it. The peptides page says $199/mo and the homepage says $249/mo, both live on the same day. Sermorelin does the same thing at $249 against $349. Nothing on the site reconciles either pair.
Glossary
Key terms
Show definitions
- Certificate of analysis
- A laboratory report for one manufactured lot, giving identity, potency and sterility results against a specification. It describes the lot it was run on and says nothing about any other lot.
- 503A
- The section of the Food, Drug, and Cosmetic Act covering a preparation compounded by a state-licensed pharmacy against a prescription for one named patient. Alinwell never uses this term, or 503B, anywhere on its site.
- Beyond-use date
- The date after which a compounded preparation should not be used. It is not an expiry date in the manufactured-drug sense; it is set from the compounding date and the preparation's stability.
Compare
Others selling what Alinwell sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Alinwell's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 12 sources
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). MOTS-MET — MOTS-c registry record, phase 2, recruiting, NCT07505745. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07505745
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine 357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412; and TH9507 Extension Study, NCT00608023 — phase 3, completed, enrolment 263. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- US National Library of Medicine (2026). BPC-157 — registry record, phase 1, status unknown, NCT02637284. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02637284
- US National Library of Medicine (2026). GHK-Cu — registry record, phase 2, recruiting, acute skin wound healing, NCT07437586; the completed GHK-Cu record is a 27-participant study of facial skin quality, and no registry record studies hair. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437586
- US National Library of Medicine (2026). ClinicalTrials.gov intervention search: "Epithalon", "Epitalon" and "Epithalamin" — zero studies under any spelling; PubMed restricted to randomized controlled trial[pt] — zero records. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=Epithalon
- US National Library of Medicine (2026). TESTS — The Efficacy and Safety of Ta1 for Sepsis, NCT02867267, phase 3, completed, enrolment 1,106. Intervention search "thymalfasin OR thymosin alpha-1" returned 64 studies, in hepatitis, sepsis, pancreatitis, cirrhosis and oncology. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02867267
- US National Library of Medicine (2026). PubMed search: (delta sleep-inducing peptide OR DSIP) AND randomized controlled trial[pt] — 7 records, two of them false positives, the two genuine sleep trials published 1981 and 1992 in chronic insomnia; ClinicalTrials.gov intervention search — zero DSIP studies. The same searches run for tirzepatide in the same pass returned 134 randomized-trial records and 278 registry studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=%28delta+sleep-inducing+peptide+OR+DSIP%29+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov intervention search: zero records naming Semax and zero naming Selank. PubMed: 207 records mentioning Semax, one carrying the randomized-controlled-trial publication type (2007, motor neuron disease); 68 mentioning Selank, two randomized trials, both in anxiety disorders. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=Semax
- Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.